{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:05:07Z","timestamp":1791036307004,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.leukres.2010.03.039","type":"journal-article","created":{"date-parts":[[2010,4,21]],"date-time":"2010-04-21T08:44:50Z","timestamp":1271839490000},"page":"1647-1655","source":"Crossref","is-referenced-by-count":32,"title":["Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Tim","family":"Luetkens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipe","family":"Schafhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike","family":"Uhlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Stasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruken","family":"Akbulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta M.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"York","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Gontarewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Gordic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Lajmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanran","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.03.039_bib1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.03.039_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.03.039_bib3","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.03.039_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.03.039_bib5","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.03.039_bib6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.5858\/2006-130-669-IROAO","article-title":"Imatinib resistance: obstacles and opportunities","volume":"130","author":"Litzow","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.leukres.2010.03.039_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia: diagnosis and treatment","volume":"81","author":"Quintas-Cardama","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.leukres.2010.03.039_bib8","first-page":"93","article-title":"Detection of BCR-ABL mutations and resistance to imatinib mesylate","volume":"125","author":"Branford","year":"2006","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.leukres.2010.03.039_bib9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2006.03.012","article-title":"Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era","volume":"12","author":"Grigg","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.leukres.2010.03.039_bib10","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.03.039_bib11","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2010.03.039_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.03.039_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V100.2.397","article-title":"Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose","volume":"100","author":"Guglielmi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.039_bib14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/blood.V94.2.434","article-title":"T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation","volume":"94","author":"Drobyski","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.039_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol Rev"},{"key":"10.1016\/j.leukres.2010.03.039_bib16","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/sj.leu.2402278","article-title":"MAGE-A genes are not expressed in human leukemias","volume":"15","author":"Chambost","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.03.039_bib17","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.1993.tb03111.x","article-title":"A tumour-associated antigen expression in human haematological malignancies","volume":"84","author":"Chambost","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.03.039_bib18","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.bjc.6690824","article-title":"Expression of testicular genes in haematological malignancies","volume":"81","author":"Lim","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2010.03.039_bib19","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1038\/sj.leu.2402732","article-title":"Frequent expression of HAGE in presentation chronic myeloid leukaemias","volume":"16","author":"Adams","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.03.039_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.leukres.2006.06.022","article-title":"PRAME mRNA levels in cases with chronic leukemia: clinical importance and review of the literature","volume":"31","author":"Paydas","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.03.039_bib21","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood-2008-03-144071","article-title":"Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia","volume":"113","author":"Rezvani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.039_bib22","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2008-04-150045","article-title":"Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia","volume":"112","author":"Quintarelli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.039_bib23","first-page":"1766","article-title":"Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2019-deoxycytidine","volume":"54","author":"Weber","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.03.039_bib24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1158\/1541-7786.MCR-05-0229","article-title":"Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells","volume":"4","author":"Wischnewski","year":"2006","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.leukres.2010.03.039_bib25","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1158\/0008-5472.CAN-04-1442","article-title":"Intratumor heterogeneity of cancer\/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2\u2019-deoxycytidine","volume":"64","author":"Sigalotti","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2010.03.039_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/38664","article-title":"Histone acetylation in chromatin structure and transcription","volume":"389","author":"Grunstein","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2010.03.039_bib27","article-title":"Cancer-testis antigens MAGE-C1\/CT7 and MAGE-A3 promote the survival of multiple myeloma cells","author":"Atanackovic","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.03.039_bib28","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.187.8.1349","article-title":"A survey of the humoral immune response of cancer patients to a panel of human tumor antigens","volume":"187","author":"Stockert","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.leukres.2010.03.039_bib29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00277-008-0477-9","article-title":"Current status of epigenetic treatment in myelodysplastic syndromes","volume":"87","author":"Kuendgen","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2010.03.039_bib30","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2174\/0929867043365099","article-title":"Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view","volume":"11","author":"Vanhaecke","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.leukres.2010.03.039_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.pharmtox.45.120403.095825","article-title":"Clinical development of histone deacetylase inhibitors as anticancer agents","volume":"45","author":"Drummond","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.leukres.2010.03.039_bib32","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.leukres.2006.02.031","article-title":"PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma","volume":"30","author":"Proto-Siqueira","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.03.039_bib33","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/gb-2008-9-9-r139","article-title":"Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues","volume":"9","author":"Kilpinen","year":"2008","journal-title":"Genome Biol"},{"key":"10.1016\/j.leukres.2010.03.039_bib34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00277-008-0514-8","article-title":"Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia","volume":"87","author":"Ortmann","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2010.03.039_bib35","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/gcc.20465","article-title":"Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies","volume":"46","author":"Schenk","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.leukres.2010.03.039_bib36","first-page":"1810","article-title":"Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group","volume":"91","author":"Gale","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.039_bib37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bmt.1700933","article-title":"Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"20","author":"van Rhee","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2010.03.039_bib38","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.039_bib39","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1046\/j.1365-2141.2001.02670.x","article-title":"Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia","volume":"112","author":"Matsushita","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.03.039_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.20425","article-title":"PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects","volume":"79","author":"Paydas","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2010.03.039_bib41","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1046\/j.1365-2141.1998.00982.x","article-title":"PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells","volume":"102","author":"van Baren","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.03.039_bib42","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0301-472X(00)00550-6","article-title":"Simultaneous expression of different immunogenic antigens in acute myeloid leukemia","volume":"28","author":"Greiner","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2010.03.039_bib43","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2010.03.039_bib44","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1182\/blood-2008-07-170282","article-title":"The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.039_bib45","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.leukres.2010.03.039_bib46","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.039_bib47","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","article-title":"Chronic myelogenous leukemia: mechanisms underlying disease progression","volume":"16","author":"Shet","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.03.039_bib48","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.03.039_bib49","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1038\/sj.jid.5700836","article-title":"Epigenetic control of MAGE gene expression by the KIT tyrosine kinase","volume":"127","author":"Yang","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.leukres.2010.03.039_bib50","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer","volume":"99","author":"Epping","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2010.03.039_bib51","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/ijc.23758","article-title":"Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas","volume":"123","author":"Partheen","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2010.03.039_bib52","first-page":"1","article-title":"Cancer\/testis (CT) antigens - a new link between gametogenesis and cancer","volume":"1","author":"Old","year":"2001","journal-title":"Cancer Immun"},{"key":"10.1016\/j.leukres.2010.03.039_bib53","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00262-009-0733-4","article-title":"A systematic review of humoral immune responses against tumor antigens","volume":"58","author":"Reuschenbach","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.leukres.2010.03.039_bib54","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1172\/JCI28546.","article-title":"Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis","volume":"116","author":"Paniagua","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2010.03.039_bib55","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1002\/art.21424","article-title":"Amelioration of autoimmune nephritis by imatinib in MRL\/lpr mice","volume":"52","author":"Sadanaga","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.leukres.2010.03.039_bib56","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","article-title":"Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells","volume":"103","author":"Appel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.039_bib57","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.039_bib58","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.4049\/jimmunol.178.4.2028","article-title":"Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo","volume":"178","author":"Sinai","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.leukres.2010.03.039_bib59","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2006-04-018705","article-title":"Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections","volume":"108","author":"Mumprecht","year":"2006","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610001803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610001803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T11:47:29Z","timestamp":1635248849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610001803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0145212610001803"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.03.039","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}